Gaucher Disease News and Research

RSS
Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Shire submits REPLAGAL BLA with the FDA

Shire submits REPLAGAL BLA with the FDA

Shire submits a MAA for velaglucerase alfa in Europe

Shire submits a MAA for velaglucerase alfa in Europe

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Preliminary Phase 2 study results of Plicera drug released

Preliminary Phase 2 study results of Plicera drug released

Blood vessels around the brain now converted into production/delivery systems

Blood vessels around the brain now converted into production/delivery systems

Protalix Biotherapeutics reports completion of its Phase III trial of prGCD

Protalix Biotherapeutics reports completion of its Phase III trial of prGCD

Protalix receives orphan drug designation for prGCD

Protalix receives orphan drug designation for prGCD

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme updates on Cerezyme supply plus 2009 financials

One injection of gene therapy spreads through brain in animal study

One injection of gene therapy spreads through brain in animal study